Janux Therapeutics Investor Relations Material
Latest events
Status Update
Janux Therapeutics
Q1 2025
8 May, 2025
Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Janux Therapeutics Inc
Access all reports
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to create targeted therapies that activate the immune system specifically within the tumor microenvironment, minimizing systemic side effects. Janux Therapeutics is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Key slides for Janux Therapeutics Inc
Status Update
Janux Therapeutics Inc
Status Update
Janux Therapeutics Inc
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
JANX
Country
🇺🇸 United States